Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | MS therapies: limited direct effect in CNS pathology

Augusto A. Miravalle, MD, FAAN, University of Colorado School of Medicine, Aurora, CO, discusses how current agents used for the treatment of multiple sclerosis (MS) don’t target all the components of MS pathology. Currently, available medications are only affecting a small portion of the pathophysiology of MS, predominantly peripheral activation of B-cells, antigen presentation, and CNS penetration. Still, they have limited effect in direct CNS pathology. There is a recent interest in looking into the role of other cells, particularly innate immune cells such as microglial cells, and understanding their role in the compartmentalized inflammatory response, a major mechanism driving progressive MS. The lack of agents targeting chronic smoldering inflammation is an unmet need in the MS space, and several agents are being investigated to address this need. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Miravalle received consulting honoraria, speaker honoraria and/or research funding from: Alexion, EMD Serono, Genentech, BMS, Horizon, Novartis, Biogen, MF Foundation, MSAA, CanDo MS, American Academy of Neurology.